Crinetics Pharmaceuticals, Inc. (CRNX) Dividend History

Company News

• Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

  Crinetics Pharmaceuticals presented long-term clinical data on PALSONIFY, an oral medication for acromegaly, showing sustained IGF-1 level control and stable patient symptoms across two Phase 3 clinical trials.

  GlobeNewswire Inc.
• Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

  The FDA has approved Neurocrine Biosciences' Crenessity as the first targeted treatment for classic congenital adrenal hyperplasia (CAH), a rare inherited disorder. Analysts see significant potential for Crenessity to become a blockbuster drug, but stress the need for education on glucocorticoid dose reduction.

  Benzinga

  Featured Companies: NBIX
• Crinetics Pharmaceuticals exec sells shares worth over $645,000 - Investing.com

  Crinetics Pharmaceuticals' Chief Medical and Development Officer Dana Pizzuti sold over $645,000 worth of shares, exercising options and selling the acquired shares. The transaction was part of a pre-arranged trading plan, and Pizzuti still holds a significant stake in the company.

  Investing.com
• Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates

  Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: NOTV
• Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?

  Despite good results in phase 3 trials, there are barriers to its drug candidate's success.

  The Motley Fool